I

Innate Pharma SA
D

IPHA

2.23000
USD
-0.02
(-0.89%)
مغلق
حجم التداول
1,627
الربح لكل سهم
-1
العائد الربحي
-
P/E
-5
حجم السوق
186,900,227
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ARCT
    0.846
    (5.00%)
    17.770 USD
    BNTX
    BNTX
    2.240
    (1.90%)
    120.100 USD
    GSK
    GSK
    -0.320
    (-0.87%)
    36.650 USD
    JNJ
    JNJ
    2.680
    (1.68%)
    162.370 USD
    MRK
    MRK
    1.820
    (2.08%)
    89.500 USD
    MRNA
    MRNA
    1.785
    (5.29%)
    35.535 USD
    N
    NVAX
    0.05500
    (0.69%)
    7.98000 USD
    PFE
    PFE
    0.405
    (1.56%)
    26.305 USD
    المزيد
الأخبار
المقالات

العنوان: Innate Pharma SA

القطاع: Healthcare
الصناعة: Biotechnology
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.